Sorrento Therapeutics Analyst Ratings
Sorrento Therapeutics Analyst Ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
11/02/2022 | 216.46% | Cantor Fitzgerald | → $5 | Initiates Coverage On | → Overweight |
03/25/2022 | 1165.82% | HC Wainwright & Co. | $26 → $20 | Maintains | Buy |
08/09/2021 | 1545.57% | HC Wainwright & Co. | $30 → $26 | Maintains | Buy |
01/21/2021 | 2115.19% | Alliance Global Partners | → $35 | Initiates Coverage On | → Buy |
07/31/2020 | 1798.73% | HC Wainwright & Co. | $24 → $30 | Maintains | Buy |
05/26/2020 | 1418.99% | Dawson James | → $24 | Initiates Coverage On | → Buy |
03/30/2020 | 1418.99% | HC Wainwright & Co. | $28 → $24 | Reiterates | → Buy |
10/07/2019 | 1229.11% | JMP Securities | → $21 | Initiates Coverage On | → Market Outperform |
03/20/2019 | 659.49% | B. Riley Securities | $10.5 → $12 | Maintains | Buy |
06/28/2018 | 801.9% | B. Riley Securities | → $14.25 | Initiates Coverage On | → Buy |
04/03/2018 | 2431.65% | HC Wainwright & Co. | $38 → $40 | Maintains | Buy |
11/15/2017 | 279.75% | Oppenheimer | $7 → $6 | Maintains | Outperform |
日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
---|---|---|---|---|---|
11/02/2022 | 216.46% | 康托·菲茨杰拉德 | →$5 | 开始承保 | →超重 |
03/25/2022 | 1165.82% | HC Wainwright公司 | $26→$20 | 维护 | 买 |
08/09/2021 | 1545.57% | HC Wainwright公司 | $30→$26 | 维护 | 买 |
2021/01/21 | 2115.19% | 联盟全球合作伙伴 | →$35 | 开始承保 | →购买 |
07/31/2020 | 1798.73% | HC Wainwright公司 | $24→$30 | 维护 | 买 |
05/26/2020 | 1418.99% | 道森·詹姆斯 | →$24 | 开始承保 | →购买 |
03/30/2020 | 1418.99% | HC Wainwright公司 | $28→$24 | 重申 | →购买 |
2019/07/10 | 1229.11% | JMP证券 | →$21 | 开始承保 | →市场跑赢大盘 |
2019/03/20 | 659.49% | B.莱利证券 | $10.5→$12 | 维护 | 买 |
2018/06/28 | 801.9% | B.莱利证券 | →$14.25 | 开始承保 | →购买 |
2018年03月04日 | 2431.65% | HC Wainwright公司 | $38→$40 | 维护 | 买 |
2017年11月15日 | 279.75% | 奥本海默 | $7→$6 | 维护 | 跑赢大盘 |
Sorrento Therapeutics Questions & Answers
索伦托治疗公司问答
The latest price target for Sorrento Therapeutics (NASDAQ: SRNE) was reported by Cantor Fitzgerald on November 2, 2022. The analyst firm set a price target for $5.00 expecting SRNE to rise to within 12 months (a possible 216.46% upside). 2 analyst firms have reported ratings in the last year.
索伦托治疗公司(纳斯达克:SRNE)的最新目标价是由坎托·菲茨杰拉德于2022年11月2日报道的。这家分析公司将目标价定为5美元,预计SRNE将在12个月内升至(可能上涨216.46%)。去年有两家分析公司公布了评级。
The latest analyst rating for Sorrento Therapeutics (NASDAQ: SRNE) was provided by Cantor Fitzgerald, and Sorrento Therapeutics initiated their overweight rating.
索伦托治疗公司(纳斯达克代码:SRNE)的最新分析师评级由坎托·菲茨杰拉德提供,索伦托治疗公司启动了他们的增持评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Sorrento Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Sorrento Therapeutics was filed on November 2, 2022 so you should expect the next rating to be made available sometime around November 2, 2023.
分析师在进行了广泛的研究后得出股票评级,其中包括查阅公共财务报表,与索伦托治疗公司的高管和客户交谈,以及听取收益电话会议。大多数分析师每三个月就会这样做一次,所以你每年应该会得到每家公司每家公司的4个评级。索伦托治疗公司的上一次评级是在2022年11月2日提交的,所以你应该预计下一次评级将在2023年11月2日左右的某个时候提供。
While ratings are subjective and will change, the latest Sorrento Therapeutics (SRNE) rating was a initiated with a price target of $0.00 to $5.00. The current price Sorrento Therapeutics (SRNE) is trading at is $1.58, which is within the analyst's predicted range.
虽然评级是主观的,并将发生变化,但最新的索伦托治疗公司(SRNE)评级是以0.00美元至5.00美元的目标价启动的。索伦托治疗公司(SRNE)目前的交易价格为1.58美元,在分析师的预测范围内。